Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer

Published:2006-06 Issue:2 Volume:7 Page:107-113
ISSN:1618-7598
Container-title:The European Journal of Health Economics
language:en
Short-container-title:Eur J Health Econ

Author:

Limat Samuel,Bracco-Nolin Claire-Hélène,Legat-Fagnoni Christine,Chaigneau Loic,Stein Ulrich,Huchet Bernard,Pivot Xavier,Woronoff-Lemsi Marie-Christine

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s10198-006-0338-1.pdf

Reference36 articles.

1. André T, Boni C, Mounedjil-Boudiaf L et al. (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

2. Arkenau H, Schmoll H, Kubicka S et al. (2005) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of a safety and efficacy analysis (abstract). J Clin Oncol 23:247

3. Borner M, Scheithauer W, Twelves C et al. (2001) Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 6 [Suppl 4]:12–16

4. Bouvier V, Reaud JM, Gignoux M et al. (2003) Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Département, France. Eur J Health Econ 4:102–106

5. Braun M, Adab F, Bradley C et al. (2003) Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer 89:1155–1158

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia;Internal Medicine Journal;2024-07-04

2. Management of patients with metastatic colorectal cancer in Lebanese hospitals and associated direct cost: a multicentre cohort study;Eastern Mediterranean Health Journal;2019-07-01

3. Real-world resource use and costs of adjuvant treatment for stage III colon cancer;European Journal of Cancer Care;2013-12-25

4. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden – A clinical practice model approach;Acta Oncologica;2012-08-31

5. Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato;PharmacoEconomics - Italian Research Articles;2012-07